[1]宋志霞,饶毅峰△,刘阳,等.黄芪甲苷对糖尿病肾病大鼠足细胞裂孔隔膜的保护作用[J].西部中医药,2020,33(01):13.[doi:10.12174/j.issn.1004-6852.2020.01.04]
　SONG Zhixia,RAO Yifeng,LIU Yang,et al.Protective Effects of Astragaloside IV on Podocyte Slit Diaphragm of the Rats with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2020,33(01):13.[doi:10.12174/j.issn.1004-6852.2020.01.04]
点击复制

黄芪甲苷对糖尿病肾病大鼠足细胞裂孔隔膜的保护作用
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年01期
页码:
13
栏目:
出版日期:
2020-01-15

文章信息/Info

Title:
Protective Effects of Astragaloside IV on Podocyte Slit Diaphragm of the Rats with Diabetic Nephropathy
文章编号:
1004-6852(2020)01-0013-06
作者:
宋志霞，饶毅峰△，刘阳，夏蓉，徐双双，杨林
宜昌市中心人民医院/三峡大学第一临床医学院肾病内科，湖北 宜昌 443000
Author(s):
SONG Zhixia, RAO Yifeng△, LIU Yang, XIA Rong, XU Shuangshuang, YANG Lin
Department of Nephrology, the First Clinical College, Three Gorges University/Yichang City Central People′s Hospital, 443000 China
关键词:
肾病; 糖尿病; 足细胞; 裂孔隔膜蛋白; Nephrin; Podocin; 黄芪甲苷; 大鼠
Keywords:
nephropathy;  diabetic;  podocyte;  slit diaphragm protein;  Nephrin;  Podocin;  astragaloside IV;  rats
分类号:
R587.2
DOI:
10.12174/j.issn.1004-6852.2020.01.04
文献标志码:
A
摘要:
目的：探讨黄芪甲苷对糖尿病肾病(diabetic nephropathy，DN)大鼠足细胞裂孔膈膜的保护作用及其可能机制。方法：利用腹腔注射链脲佐菌素(streptozotocin，STZ)建立糖尿病大鼠模型。将40只雄性SD大鼠随机分为4组各10只：正常对照组(NC组)、黄芪甲苷组(astragaloside IV，AS-IV组)、糖尿病肾病组(DN组)和糖尿病肾病+黄芪甲苷干预组(DN+AS-IV组)。造模成功后每6、12周检测大鼠体质量及24小时尿蛋白量。造模后12周末留取大鼠血样本和肾组织标本并处死大鼠。检测大鼠肌酐(serum creatinine，SCr)、尿素氮(blood urea nitrogen，BUN)和尿蛋白；PAS及Masson染色观察肾脏病理改变；电镜观察足细胞超微结构变化；免疫组化法及Western Blot法检测肾组织Nephrin、Podocin、Desmin表达。结果：与DN组相比黄芪甲苷可明显降低大鼠蛋白尿，改善大鼠肾脏病理损伤。DN组Nephrin、Podocin蛋白表达量均低于NC组(P＜0.05)，Desmin蛋白表达量高于NC组(均P＜0.05)，AS-IV组肾脏病理改变及各指标明显改善，差异有统计学意义(P＜0.05)。结论：黄芪甲苷可能通过稳定足细胞裂孔隔膜蛋白Nephrin和Podocin来抑制STZ诱导的糖尿病大鼠肾脏损伤。
Abstract:
Objective: To explore the protective effects of astragaloside IV on podocyte impairment of the rats with diabetic nephropathy(DN) and the potential mechanism. Methods: After establishing DM rat models by peritoneal injection of STZ, forty male SD rats were randomized into four groups: normal control group (NC group), astragaloside IV group(AS-IV group), DN group and DN+AS-IV group, ten rats each group. After establishing the rat models successfully, to detect body mass and 24 hours urinary protein content each six and 12 weeks. By the end of 12 weeks, the rats were sacrificed after keeping the samples of blood and renal tissue. To measure SCr, BUN and urinary protein of the rats; PAS and Masson staining were used to observe renal pathological changes; electron microscope was used to observe podocyte ultrastructure changes; immunohistochemical method and Western Blot method were adopted to detect the expressions of Nephrin, Podocin and Desmin in renal tissue. Results: Compared with DN group, astragaloside IV could obviously reduce proteinuria of the rats, improve renal pathological damage. The expressions of Nephrin and Podocin protein in DN group were lower than these of NC group (P＜0.05), Desmin protein expressions were higher than these of NC group(all P＜0.05), the chages above in AS-IV group were notable, and the difference had statistical meaning(P＜0.05). Conclusion: Astragaloside IV could inhibit renal damage of STZ-induced DM rat models by stablizing podocyte slit diaphragm protein Nephrin and Podocin.

相似文献/References:

[1]段尚勤.糖脂消合罗格列酮治疗2型糖尿病合并非酒精性脂肪肝疗效观察[J].西部中医药,2013,26(02):88.
　DUAN Shangqin.Clinical Observation on TangZhiXiao and Rosiglitazone Maleate in Treating Type 2 Diabetes Mellitus Complicated with Non Alcoholic Fatty Liver Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(01):88.
[2]贾晓杰,刘志跃△.红花制剂在糖尿病及其并发症中的研究进展[J].西部中医药,2013,26(03):127.
　JIA Xiaojie,LIU Zhiyue.Research Progress of Safflower Preparation in Diabetes Mellitus and the Complication[J].Western Journal of Traditional Chinese Medicine,2013,26(01):127.
[3]张军和,杨振亚,张永琴.安糖1号治疗初发2型糖尿病并代谢综合征40例临床观察[J].西部中医药,2013,26(05):1.
　ZHANGJunhe,YANGZhenya,ZHANGYongqin.ClinicalObservationonAnTangNo.1intheTreatmentfor40CasesofDiabetesMellitusTypeTwoatPrimaryStageComplicatedwithMetabolismSyndrome[J].Western Journal of Traditional Chinese Medicine,2013,26(01):1.
[4]吕志芹,魏文慧.胰岛素联合痰热清治疗2型糖尿病合并肺部感染49例[J].西部中医药,2013,26(06):85.
　LV Zhiqin,WEI Wenhui.Insulin and TanReQing Injection in Treating 49 Cases of Diabetes Mellitus Type Two Complicated with Pulmonary Infection[J].Western Journal of Traditional Chinese Medicine,2013,26(01):85.
[5]范宗慧.温肾健脾法治疗糖尿病心得[J].西部中医药,2012,25(09):43.
　FAN Zong-hui.Experience on Method of WenShen JianPi in Treating Diabetes[J].Western Journal of Traditional Chinese Medicine,2012,25(01):43.
[6]张国民.消渴清颗粒治疗糖尿病周围神经病变疗效分析[J].西部中医药,2012,25(08):66.
　ZHANG Guo-min.XiaoKeQing Granules in Treating Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2012,25(01):66.
[7]张载宏.丹红注射液联合多贝斯治疗糖尿病周围神经病变临床疗效观察[J].西部中医药,2013,26(07):74.
　ZHANG Zaihong.Clinical Observation on DanHong Injection and Calcium Dobesilate Capsules in Treating Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):74.
[8]段丽萍.中西医结合治疗糖尿病周围神经病变30例[J].西部中医药,2013,26(07):90.
　DUAN Liping.Integrative Medicine in Treating 30 Cases of Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(01):90.
[9]刘希宏.中西药物联用对老年高血压合并2型糖尿病患者肾功能的保护作用[J].西部中医药,2012,25(07):9.
　LIU Xi-hong.Protection of Integrated Traditional Chinese and Western Medicine on Renal Function of Patients with Senile Hypertension and Type 2 Diabetes Mellitus[J].Western Journal of Traditional Chinese Medicine,2012,25(01):9.
[10]龚云,王超,亢建国.运动结合灵芝多糖干预对糖尿病大鼠血脂的影响[J].西部中医药,2013,26(08):8.
　GONG Yun,WANG Chao,KANG Jianguo.Effects of Exercise and Ganoderan Intervention on Blood Fat of Rats with Diabetes Mellitus[J].Western Journal of Traditional Chinese Medicine,2013,26(01):8.
[11]都静,张晓明.血清脂蛋白(α)及胱抑素C与早期糖尿病肾病中医证型的相关性分析[J].西部中医药,2019,32(06):1.
　DU Jing,ZHANG Xiaoming.Analysis on the Correlation between Lipoprotein α,Cystatin C and TCM Patterns of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2019,32(01):1.
[12]杨红云.中医临床护理路径对老年糖尿病肾病患者疗效及血糖水平、体质指数的影响[J].西部中医药,2020,33(01):136.[doi:10.12174/j.issn.1004-6852.2020.01.36]
　YANG Hongyun.Influence of TCM Clinical Nursing Pathway on Clinical Effects, Blood Glucose Level and Body Mass Index of Senile Patients with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2020,33(01):136.[doi:10.12174/j.issn.1004-6852.2020.01.36]
[13]张东鹏,张定华,连琯,等.益气养阴通络法治疗糖尿病肾病的研究进展[J].西部中医药,2021,34(04):150.[doi:10.12174/j.issn.2096-9600.2021.04.37]
　ZHANG Dongpeng,ZHANG Dinghua,LIAN Guan,et al.Research Progress of Invigorating Qi Nourishing Yin and Dredging Collaterals Method in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2021,34(01):150.[doi:10.12174/j.issn.2096-9600.2021.04.37]

备注/Memo

备注/Memo:
收稿日期：2019-03-27*基金项目：国家自然科学基金青年科学基金项目(81600567)；宜昌市科学技术局项目(A16-301-02)。作者简介：宋志霞(1980—)，女，博士学位，副主任医师。研究方向：糖尿病肾病早期防治。△通讯作者：饶毅峰(1979—)，男，硕士学位，副主任医师。研究方向：终末期肾病的诊治。
更新日期/Last Update: 2020-01-15